TRCT
INM icon

Tower Research Capital (TRC)’s InMed Pharmaceuticals INM Stock Holding History

Tower Research Capital (TRC)’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-400
Closed -$1.3K – 5408
2025
Q2 		$1.3K Buy
+400
New +$1.11K ﹤0.01% 4831
2022
Q4 		– Sell
-53
Closed -$7K – 6132
2022
Q3 		$7K Buy
+53
New +$9.8K ﹤0.01% 4891

Other funds holding INM

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Tower Research Capital (TRC)'s INM Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of InMed Pharmaceuticals (INM) in Q3 2025, closing a stake of 400 shares — an estimated $1.3K sold.

Tower Research Capital (TRC) first reported a position in INM in Q3 2022 and held it in 2 quarters. The position peaked at $7K in Q3 2022. 9 funds tracked by Wall St. Rank hold INM as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining InMed Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 400 InMed Pharmaceuticals shares in Q3 2025, an estimated $1.3K.
  • Tower Research Capital (TRC) first reported a position in InMed Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Tower Research Capital (TRC)'s InMed Pharmaceuticals position peaked at $7K in Q3 2022.
  • 9 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.